Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]Ac-SibuDAB
- Development stage
- Preclinical
- Lead developer
- Paul Scherrer Institute
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[225Ac]Ac-SibuDAB is an experimental radiopharmaceutical designed for targeted alpha-therapy (TAT) of prostate cancer. It consists of the alpha-emitting radioisotope actinium-225 complexed with SibuDAB, a small-molecule ligand that targets Prostate-Specific Membrane Antigen (PSMA). SibuDAB is uniquely engineered with an albumin-binding moiety (derived from ibuprofen) to enhance its pharmacokinetic profile by extending its half-life in the blood. This prolonged circulation allows for greater accumulation in PSMA-expressing tumor tissues compared to conventional ligands like PSMA-617. Preclinical data indicate that [225Ac]Ac-SibuDAB provides superior therapeutic efficacy and tumor eradication in mouse models of prostate cancer, making it a promising candidate for treating metastatic disease.
- Other names
- actinium-225-labeled SibuDABactinium225-labeled SibuDABactinium 225-labeled SibuDAB225Ac-SibuDAB
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [225Ac]Ac-SibuDAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [225Ac]Ac-SibuDAB.